Effect of Longdan Xiegan Decoction combined with triple therapy on serum PG and IL-8 expression in patients with chronic gastritis infected by Hp
-
摘要: 目的 研究龙胆泻肝汤联合三联疗法对Hp感染慢性胃炎患者血清胃蛋白酶原(PG)及白细胞介素8(IL-8)表达的影响。方法 选择2019年3月—2020年4月收治的Hp感染慢性胃炎患者160例，随机分为对照组(80例)和研究组(80例)。对照组患者给予常规西医三联疗法：雷贝拉唑钠肠溶胶囊+阿莫西林肠溶片+克拉霉素分散片，研究组患者增加龙胆泻肝汤。2组均治疗2周，评价2组患者临床疗效和Hp根除情况。分别于治疗前和治疗后第2天，采用HIT-91A荧光免疫分析仪测定患者血清中PGⅠ和PGⅡ，并计算PGⅠ/ PGⅡ(PGR)，采用双抗体夹心酶联免疫吸附法测定血清IL-8水平。记录患者在治疗期间的不良反应发生情况，随访1年，记录复发情况。结果 研究组临床治疗总有效率为88.75%，明显高于对照组的75.00%(P< 0.05)；研究组Hp根除率为85.00%，明显高于对照组的68.75%(P< 0.05)。治疗后，2组患者血清PGⅠ水平和PGR均显著增加，PGⅡ和IL-8水平均显著降低，且研究组PGⅠ水平和PGR均显著高于对照组，PGⅡ和IL-8水平均显著低于对照组(P< 0.05)。治疗期间研究组总不良反应发生率为5.00%，显著低于对照组的25.00%(P< 0.05)。随访1年内，研究组复发率为6.25%，显著低于对照组的20.00%(P< 0.05)。结论 龙胆泻肝汤联合三联疗法可以显著提高Hp感染慢性胃炎患者的临床治疗效果，提高Hp根除率，改善血清中PG及IL-8的表达水平。Abstract: Objective To study the effect of Longdan Xiegan Decoction combined with triple therapy on the expression of serum pepsinogen(PG) and interleukin 8(IL-8) in patients with chronic gastritis infected by Helicobacter pylori(Hp).Methods A total of 160 patients with chronic gastritis infected by Hp treated from March 2019 to April 2020 were randomly divided into control group(80 cases) and study group(80 cases). Patients in the control group were given conventional triple therapy of frontal and western medicine: rabeprazole sodium enteric-coated capsules + amoxicillin enteric-coated tablets + clarithromycin dispersible tablets. Patients in the study group were given Longdan Xiegan Decoction on the basis of the control group. Both groups were treated for 2 weeks. The clinical efficacy and Hp eradication of the two groups were evaluated. Before treatment and on the second day after treatment, the levels of PGⅠ and PGⅡ in serum were measured by HIT-91A fluorescence immunoassay analyzer, and PGⅠ/PGⅡ(PGR) was calculated. The levels of serum IL-8 were measured by double antibody sandwich enzyme-linked immunosorbent assay. The incidence of adverse events during the treatment was recorded and the recurrence rate was recorded followed up for 1 year.Results The total effective rate of clinical treatment in the study group was 88.75%, which was significantly higher than 75.00% in the control group(P< 0.05). The eradication rate of Hp in the study group was 85.00%, which was significantly higher than 68.75% in the control group(P< 0.05). After treatment, the level of PGⅠ and PGR in serum of the two groups increased significantly, and the levels of PGⅡ and IL-8 in serum of the two groups decreased significantly(P< 0.05). And the level of PGⅠ and PGR in the study group were significantly higher than those in the control group, and the levels of PGⅡ and IL-8 in the study group were significantly lower than those in the control group(P< 0.05). During the treatment period, the total incidence of adverse events in the study group was 5.00%, which significantly lower than 25.00% in the control group(P< 0.05). Within 1 year of follow-up, the recurrence rate in the study group was 6.25%, which was significantly lower than 20.00% in the control group(P< 0.05).Conclusion Longdan Xiegan Decoction combined with triple therapy can significantly improve the clinical treatment effect of patients with chronic gastritis infected by Hp, increase the eradication rate of Hp, and improve the expression of serum IL-8 and PG.
-
Key words:
- Longdan Xiegan Decoction /
- Helicobacter pylori /
- chronic gastritis /
- pepsinogen /
- interleukin-8
-
-
表 1 2组患者临床疗效比较
组别 例数 治愈/例 显效/例 有效/例 无效/例 总有效率/% 对照组 80 16 22 22 20 75.00 研究组 80 21 26 24 9 88.75 χ2 5.096 P 0.024 
下载: 导出CSV
表 2 2组患者Hp根除情况比较
组别 例数 阳性/例 阴性/例 根除率/% 对照组 80 25 55 68.75 研究组 80 12 68 85.00 χ2 5.492 P 0.015
下载: 导出CSV
表 3 2组患者治疗前后血清中PG及IL-8水平变化情况比较
X±S 组别 例数 PGⅠ/(μg·L-1) PGⅡ/(μg·L-1) PGR IL-8/(pg·mL-1) 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 对照组 80 39.45±4.34 57.23± 5.03 17.17±3.44 15.88± 3.62 2.42±1.00 3.57± 1.32 134.23±18.48 87.87± 7.34 研究组 80 40.12±4.76 67.58± 6.231) 17.223±52.00 14.69± 3.701) 2.45±0.98 4.76± 1.451) 132.39±92.00 68.49± 6.831) t 0.930 11.561 0.091 2.056 0.192 5.428 0.639 17.289 P 0.345 < 0.001 0.928 0.041 0.848 < 0.001 0.524 < 0.001 与同组治疗前比较，1)P < 0.05。
下载: 导出CSV
表 4 2组患者治疗期间不良反应发生情况比较
组别 例数 皮疹/例 头晕/例 乏力/例 胃肠道反应/例 肌肉疼痛/例 总不良反应发生率/% 对照组 80 3 4 4 5 4 25.00 研究组 80 1 1 1 1 0 5.00 χ2 12.549 P < 0.001
下载: 导出CSV
-
[1] Soyocak A, Ergun DD, Koc G, et al. Investigation of Aryl Hydrocarbon Receptor, Zinc, and Vitamin B12 Levels in Chronic Gastritis with Helicobacter pylori Infection[J]. Biol Trace Elem Res, 2021, 199(7): 2431-2437. doi: 10.1007/s12011-021-02667-5
[2] Xiong M, Luo H, Zhu W, et al. Shengyang Yiwei Decoction for the treatment of chronic gastritis: A protocol for a systematic review and meta-analysis[J]. Medicine, 2020, 99(43): e22869. doi: 10.1097/MD.0000000000022869
[3] Kobayashi J, Uchida H, Ito J. Long-term proton pump inhibitor use after Helicobacter pylori eradication may create a gastric environment for N-nitrosamine formation and gastric cancer development[J]. Gut, 2019, 68(6): 1131.
[4] 张旭艳, 白成, 陈慧群. 血清PG及IL-8联合检测对慢性胃炎患者胃黏膜损伤程度的评估价值[J]. 山东医药, 2019, 59(1): 52-54. doi: 10.3969/j.issn.1002-266X.2019.01.015
[5] 宫健伟, 李德芳, 刘鲁英, 等. 酸味补肝汤对胆汁反流性胃炎小鼠血清IL-8和胃组织COX-2及NF-κB p65表达的影响[J]. 中药新药与临床药理, 2019, 30(7): 802-805. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY201907009.htm
[6] Yan ZX, Dai YK, Ma T, et al. Efficacy of traditional Chinese medicine for chronic gastritis: A meta-analysis of randomized controlled trials[J]. Medicine, 2019, 98(20): e15710. doi: 10.1097/MD.0000000000015710
[7] Song X, He Y, Liu M, et al. Mechanism Underlying Polygonum capitatum Effect on Helicobacter pylori-associated Gastritis Based on Network Pharmacology[J]. Bioorganic Chemistry, 2021, 114(4): 105044.
[8] 任雪梅, 范凌云. 范新发化裁龙胆泻肝汤临证验案举隅[J]. 环球中医药, 2019, 12(6): 919-920. doi: 10.3969/j.issn.1674-1749.2019.06.027
[9] 于皆平, 沈志祥, 罗和生. 实用消化病学[M]. 3版. 北京: 科学出版社, 2017: 125-127.
[10] 国家中医药管理局. 中医病证诊断疗效标准[S]. 南京: 南京大学出版社, 1994: 201-202.
[11] 张声生, 唐旭东, 黄穗平, 等. 慢性胃炎中医诊疗专家共识意见(2017)[J]. 中华中医药杂志, 2017, 32(7): 3060-3064. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201707063.htm
[12] 国家中医药管理局. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 233-237.
[13] 杨振华, 孙波, 黄傲霜, 等. 慢性萎缩性胃炎中医证候的胃镜及病理特征分析研究[J]. 中国中西医结合消化杂志, 2021, 29(1): 58-61. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW202101015.htm
[14] Gong EJ, Kim DH, Ahn JY, et al. Effects of Proton Pump Inhibitor on the Distribution of Helicobacter pylori and Associated Gastritis in Patients with Gastric Atrophy[J]. Digestion, 2019, 101(3): 1-8.
[15] Yue P, Zhong J, Huang J, et al. The efficacy and safety of Xiangsha Liujunzi decoction in the treatment of chronic non-atrophic gastritis: A protocol for a systematic review and meta-analysis[J]. Medicine, 2021, 100(4): e24504. doi: 10.1097/MD.0000000000024504
[16] Shi J, Liu L, Li J, et al. Efficacy and safety of Zuojin Pill for chronic gastritis: Protocol for a systematic review of randomized controlled trials[J]. Medicine, 2020, 99(29): e21248. doi: 10.1097/MD.0000000000021248
[17] Yin X, Qiu Y, Li Z, et al. Longdan Xiegan Decoction alleviates experimental autoimmune uveitis in rats by inhibiting Notch signaling pathway activation and Th17 cell differentiation[J]. Biomed Pharmacother, 2021, 136(1): 111291.
[18] Fan X, Su Z, Nie S, et al. Efficacy and safety of Chinese herbal medicine Long Dan Xie Gan Tang in insomnia: A systematic review and meta-analysis[J]. Medicine, 2020, 99(99): e19410.
[19] Ren L, Sun D, Zhou X, et al. Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c, PPAR-alpha and AMPK-alpha[J]. J Ethnopharmacol, 2019, 232(5): 176-187.
[20] 张旭艳, 白成, 陈慧群. 血清PG及IL-8联合检测对慢性胃炎患者胃黏膜损伤程度的评估价值[J]. 山东医药, 2019, 59(1): 52-54. doi: 10.3969/j.issn.1002-266X.2019.01.015
[21] 孙政, 徐宏涛. 胃蛋白酶原, 胃泌素17作为血清学标记物对胃癌初步筛查的价值[J]. 重庆医学, 2019, 48(24): 4202-4205. doi: 10.3969/j.issn.1671-8348.2019.24.016
[22] Sanaii A, Shirzad H, Haghighian M, et al. Role of Th22 cells in Helicobacter pylori-related gastritis and peptic ulcer diseases[J]. Mol Biol Rep, 2019, 46(6): 5703-5712. doi: 10.1007/s11033-019-05004-1
[23] Mosyichuk LM, Tatarchuk OM, Simonova O, et al. Features of cytokine balance with the progression of structural changes in the gastric mucosa in patients with atrophic gastritis[J]. Gastroenterology, 2021, 55(2): 67-73. doi: 10.22141/2308-2097.55.2.2021.233625
[24] Cwa C, Lr A, Sc A, et al. Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang(1-7)/Mas axis-mediated anti-inflammatory pathway in rats[J]. J Ethnopharmacol, 2021, 274(5): 114072.
-